18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 110-119

  van Loon, Judith ^a   Grutters, Janneke P C ^a,b   Wanders, Rinus ^a   Boersma, Liesbeth ^a   Dingemans, Anne Marie C ^b   Bootsma, Gerben ^c   Geraedts, Wiel ^c   Pitz, Cordula ^d   Simons, Jean ^e   Brans, Boudewijn ^b   Snoep, Gabriel ^b   Hochstenbag, Monique ^b   Lambin, Philippe ^a   De Ruysscher, Dirk ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

^e St Jans Hospital   (Netherlands)

Author keywords

Cost effectiveness; Follow up; Non small cell lung cancer; PET

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC ASPECT; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; THORAX RADIOGRAPHY; THORAX SCINTISCANNING; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; FEMALE; HEALTH CARE COST; LONG TERM CARE; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; QUALITY OF LIFE; RADIOGRAPHY; SCINTISCANNING; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; EPIDEMIOLOGIC METHODS; FEMALE; FLUORODEOXYGLUCOSE F18; HEALTH CARE COSTS; HUMANS; LONG-TERM CARE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 71049136874     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.028     Document Type: Article

References (34)

1. Rubins J., Unger M., and Colice G.L. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132 3 Suppl. (2007) 355S-367S
2. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 7 (2003) 1285-1292
3. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung cancer 49 1 (2005) 95-108
4. Patz Jr. E.F., Connolly J., and Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 174 3 (2000) 769-774
5. van Loon J., Grutters J., Wanders R., Boersma L., Oellers M., Dingemans A.M., et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer 45 4 (2009) 588-595
6. Drummond M.F., Sculpher M.J., Torrance G.W., O'brien B., and Stoddart G.L. Methods for economic evaluation of health care programmes (2005), Oxford University Press, Oxford
7. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Making 13 4 (1993) 322-338
8. Sugimura H., and Yang P. Long-term survivorship in lung cancer: a review. Chest 129 4 (2006) 1088-1097
9. Wingo P.A., Ries L.A., Parker S.L., and Heath Jr. C.W. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 7 4 (1998) 271-282
10. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 10 (2000) 2095-2103
11. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 9 (2004) 1589-1597
12. Okamoto Y., Murakami M., Yoden E., et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys 52 2 (2002) 390-396
13. Tanvetyanon T., Robinson L.A., Schell M.J., et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 26 7 (2008) 1142-1147
14. Murillo Jr. J.R., and Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 11 10 (2006) 1095-1099
15. Guidelines for pharmaco-economic research. Diemen: Health Care Insurance Board; 2006.
16. NHS. Nice guideline costing statement: erlotinib for the treatment of NSCLC (2008), National Institute for Clinical Excellence
17. Kommer G.S.L., and Polder J. Risicosolidariteit en Zorgkosten (2005), Raad voor de Volksgezondheid en Zorg, Zoetermeer
18. Trippoli S., Vaiani M., Lucioni C., and Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in pharmacoeconomics. Pharmacoeconomics 19 8 (2001) 855-863
19. Dancey J., Shepherd F.A., Gralla R.J., and Kim Y.S. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung cancer 43 2 (2004) 183-194
20. Sensible and sustainable care (in Dutch). Zoetermeer; 2006.
21. Briggs A.C.K., and Sculpher M. Decision modelling for health economic evaluation (2006), Oxford University Press
22. Weinstein M.C. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24 11 (2006) 1043-1053
23. Fenwick E., Claxton K., and Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10 8 (2001) 779-787
24. Claxton K., Sculpher M., and Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 360 9334 (2002) 711-715
25. Edelman M.J., Meyers F.J., and Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 12 5 (1997) 318-331
26. Shih Y.C., and Halpern M.T. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?. CA Cancer J Clin 58 4 (2008) 231-244
27. Grutters J.P., Joore M.A., van der Horst F., Stokroos R.J., and Anteunis L.J. Decision-analytic modeling to assist decision making in organizational innovation: The case of shared care in hearing aid provision. Health Serv Res (2008)
28. Ubel P.A., Hirth R.A., Chernew M.E., and Fendrick A.M. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 163 14 (2003) 1637-1641
29. Buxton M.J. Economic evaluation and decision making in the UK. Pharmacoeconomics 24 11 (2006) 1133-1142
30. Benamore R., Shepherd F.A., Leighl N., et al. Does intensive follow-up alter outcome in patients with advanced lung cancer?. J Thorac Oncol 2 4 (2007) 273-281
31. Westeel V., Lebitasy M.P., Mercier M., et al. IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer. Rev Mal Respir 24 5 (2007) 645-652
32. Khan A.J., et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 81 2 (2006) 163-167
33. Oostenbrink JBC, Koopmanschap M, Rutten F. In: C.v. Zorgverzekeringen, editor. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg, 2004.
34. Tyldesley S., et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 49 4 (2001) 973-985